09 March 2009

Phendimetrazine (Bontril, Plegine, Prelu-2)

Pronunciation: fen-di-MEH-tra-zeen (also pronounced fen-dye-MEH-trah-zeen)
Chemical Abstracts Service Registry Number: 21784-30-5 (Bontril format); 569-59-5 (Plegine format); 50-58-8 (Prelu-2 format).
Formal Names: Bontril, Plegine, Prelu-2
Informal Names: Pink Hearts
Type: Stimulant (anorectic class).
Federal Schedule Listing: Schedule III (DEA no. 1615)
USA Availability: Prescription
Pregnancy Category: C

Uses.
Phendimetrazine is related to phenmetrazine. Indeed, the body converts part of a phendimetrazine dose into phenmetrazine, a fact to be remembered if employment drug screening unjustly accuses someone of using phenmetrazine. Short-term weight control is the main medical use of phendimetrazine; one experiment found it 20 more times effective than placebo— an astonishing result for any diet pill. Effectiveness declines as administration
continues, and standard practice is then to stop the drug gradually rather than increase the dosage. A derivative of the drug has been found useful for treating pyoderma gangrenosum, a skin affliction involving large sores.

Drawbacks.
If dosage suddenly stops, weariness and depression can occur. A small reduction in blood pressure is observed among some users, but generally the drug raises blood pressure and is considered inappropriate for persons with hypertension (high blood pressure). The compound has been linked with hypertension in blood circulation to lungs, a potentially fatal condition
causing trouble in breathing. Users have experienced edginess, disturbed sleep, headache, dizziness, lightheadedness, accelerated pulse rate, and feelings of heart tremors. Other muscle tremors can occur. Phendimetrazine can interfere with functioning needed to handle a car or dangerous tools. The compound can dry and even inflame the mouth, upset the stomach, loosen or tighten the bowels, and make urination frequent and painful. Persons should avoid the drug if they suffer from restlessness, glaucoma, excessive thyroid activity, heart disease, hardening of the arteries, or drug abuse. The substance may affect diabetics’ insulin needs. Overdose symptoms are similar to those of amphetamine: hyperactivity, fear, aggression, hallucination.

Abuse factors.
Phendimetrazine is a chemical relative of amphetamine and is therefore considered addictive. In an experiment using rhesus monkeys to measure phendimetrazine’s addictive potential, however, the test animals indicated no interest in it. This same study showed the drug having about 10% to 20% of dextroamphetamine’s potency.

Drug interactions.
Drinking milk can counteract phendimetrazine’s anorectic quality. The drug can dangerously increase blood pressure by interacting with monoamine oxidase inhibitors (MAOIs, found in some antidepressants and other medicine). After highly publicized incidents of adverse effects associated with combination therapy of phentermine and fenfluramine, medical practitioners became especially alert to any problems associated with diet drugs. Someone taking phendimetrazine two times a day developed heart and lung difficulty that substantially improved when dosage was halted, and a case of temporary skin rash and kidney inflammation is reported from someone who was taking phendimetrazine and phentermine. The latter drug combination is also suspected of responsibility for temporary trouble with blood circulation in the brain (leading to a stroke in at least one instance). Whether these isolated cases can be extrapolated into general principle is questionable, but such reports raise questions worthy of further scientific investigation.

Cancer.
Not enough scientific information to report.

Pregnancy.
Impact on fetal development is unknown. The drug is not recommended for pregnant women.

Additional scientific information may be found in:
Hadler, A.J. “Sustained-Action Phendimetrazine in Obesity.” Journal of Clinical Pharmacology
8 (1968): 113–17.

Mazansky, H. “A Review of Obesity and Its Management in 263 Cases.” South African
Medical Journal 49 (1975): 1955–62.

Ressler, C., and S.H. Schneider. “Clinical Evaluation of Phendimetrazine Bitartrate.”
Clinical Pharmacology and Therapeutics 2 (1961): 727–32.

Rostagno, C., et al. “Dilated Cardiomyopathy Associated with Chronic Consumption
of Phendimetrazine.” American Heart Journal 131 (1996): 407–409.

Runyan, J.W. “Observations on the Use of Phendimetrazine, a New Anorexigenic
Agent, in Obese Diabetics.” Current Therapeutic Research: Clinical and Experimental
4 (1962): 270–75.

Sash, S.E. “Anorectic Effects of OBEX LA (D-Phendimetrazine Bitartrate) in the Treatment
of Obesity.” Current Therapeutic Research: Clinical and Experimental 31 (1982):
181–84.

1 comment:

  1. Slim-Fizz is a unique appetite suppressant that contains the ground breaking fibre Glucomannan, which is an organic dissolvable fibre extracted from high quality pure Konjac.

    ReplyDelete